WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke AI-POWR wurde als Wortmarke am 29.12.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1597990 |
| Länder | 
|
| Basismarke |
Nr. 90035441,
03. Juli 2020
|
| Anmeldedatum | 29. Dezember 2020 |
| Ablaufdatum | 29. Dezember 2030 |
Markeninhaber
399 Thornall Street, 1st Floor
Edison NJ 08837
US
Edison NJ 08837
US
Markenvertreter
379 Lytton Avenue
Palo Alto CA 94301
US
Waren und Dienstleistungen
09
Computer software for using artificial intelligence, machine
learning, supervised machine learning, unsupervised machine
learning, deep learning, statistical learning, data mining,
big data analytics, predictive analytics, predictive
modeling, multivariate analytics, precision medicine,
bioinformatics, modeling, and simulation in clinical trials
or studies, designing clinical trials or studies, enriching
and enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and in the
medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field; computer
software for integrating artificial intelligence, machine
learning, supervised machine learning, unsupervised machine
learning, deep learning, statistical learning, data mining,
big data analytics, predictive analytics, predictive
modeling, multivariate analytics, precision medicine,
bioinformatics, modeling, and simulation with disease
studies and investigations, pharmaceutical and drug research
and development, biomedical, biological, and
biotechnological research and development, and pharmacology,
clinical pharmacology, system pharmacology, and system
biology; computer software for clinical trials or studies,
designing clinical trials or studies, enriching and
enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation; computer software for patient
identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation; computer software for drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, accessing, processing, and analyzing
omics, multiomics, genomics, transcriptomics, proteomics,
lipidomics, and metabolomics data, accessing, processing,
and analyzing public and proprietary omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics data, and accessing, processing, and analyzing
omics, multiomics, genomics, transcriptomics, proteomics,
lipidomics, and metabolomics data via a global computer
network using artificial intelligence, machine learning,
supervised machine learning, unsupervised machine learning,
deep learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation; computer software for disease
studies and investigations, understanding of diseases,
pharmaceutical and drug research and development,
biomedical, biological, and biotechnological research and
development, and pharmacology, clinical pharmacology, system
pharmacology, system biology research and development using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation
42
Design, development, programming, testing, maintenance,
customization, and operation of computer software in
clinical trials or studies, designing clinical trials or
studies, enriching and enhancing clinical trial or study
designs, de-risking clinical trial or study designs,
clinical trials simulations, clinical endpoint selection,
analyzing non-clinical data, preclinical data, and clinical
data, analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and in the
medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation; consulting, consultancy, and
consulting services related to clinical trials or studies,
designing clinical trials or studies, enriching and
enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and related
to the medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
platform as a service (PaaS) featuring computer platforms
and software for using artificial intelligence, machine
learning, supervised machine learning, unsupervised machine
learning, deep learning, statistical learning, data mining,
big data analytics, predictive analytics, predictive
modeling, multivariate analytics, precision medicine,
bioinformatics, modeling, and simulation in clinical trials
or studies, designing clinical trials or studies, enriching
and enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and in the
medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field; software
as a service (SaaS) featuring computer platforms for using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation in clinical trials or studies,
designing clinical trials or studies, enriching and
enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and in the
medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field; research
and development in clinical trials or studies, designing
clinical trials or studies, enriching and enhancing clinical
trial or study designs, de-risking clinical trial or study
designs, clinical trials simulations, clinical endpoint
selection, analyzing non-clinical data, preclinical data,
and clinical data, analyzing results of clinical trials or
studies, and evaluating clinical outcomes and treatment
responses, patient identification and a priori responder
selection, individualizing treatments, predicting clinical
outcomes and treatment responses, and disease diagnoses and
treatment determination, selection, and identification,
drug, drug target, and drug combination selection and
evaluation, biomarker selection, genetic analyses, omics,
multiomics, genomics, transcriptomics, proteomics,
lipidomics, and metabolomics analyses, and accessing,
processing, and analyzing omics, multiomics, genomics,
transcriptomics, proteomics, lipidomics, and metabolomics
data, and in the medical field, biomedical field, healthcare
field, pharmaceutical field, and biotechnological field
using artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation; performing clinical trials or
studies, designing clinical trials or studies, enriching and
enhancing clinical trial or study designs, de-risking
clinical trial or study designs, clinical trials
simulations, clinical endpoint selection, analyzing
non-clinical data, preclinical data, and clinical data,
analyzing results of clinical trials or studies, and
evaluating clinical outcomes and treatment responses,
patient identification and a priori responder selection,
individualizing treatments, predicting clinical outcomes and
treatment responses, and disease diagnoses and treatment
determination, selection, and identification, drug, drug
target, and drug combination selection and evaluation,
biomarker selection, genetic analyses, omics, multiomics,
genomics, transcriptomics, proteomics, lipidomics, and
metabolomics analyses, and accessing, processing, and
analyzing omics, multiomics, genomics, transcriptomics,
proteomics, lipidomics, and metabolomics data, and services
in the medical field, biomedical field, healthcare field,
pharmaceutical field, and biotechnological field using
artificial intelligence, machine learning, supervised
machine learning, unsupervised machine learning, deep
learning, statistical learning, data mining, big data
analytics, predictive analytics, predictive modeling,
multivariate analytics, precision medicine, bioinformatics,
modeling, and simulation for others (term considered too
vague by the International Bureau - Rule 13 (2) (b) of the
Regulations)
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 25. Juli 2023 | 2023/30 Gaz | CA | Ablehnung |
| 09. März 2023 | 2023/10 Gaz | JP | Ablehnung |
| 12. Januar 2023 | 2023/2 Gaz | KR | Ablehnung |
| 21. November 2022 | 2022/47 Gaz | IS | Ablehnung |
| 31. Oktober 2022 | 2022/46 Gaz | CH | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 11. Oktober 2022 | 2022/41 Gaz | CA | Ablehnung |
| 09. August 2022 | 2022/34 Gaz | BR | Ablehnung |
| 02. August 2022 | 2022/31 Gaz | KR | Ablehnung |
| 01. August 2022 | 2022/31 Gaz | MX | Ablehnung |
| 28. Juni 2022 | 2022/26 Gaz | NO | Ablehnung |
| 19. Mai 2022 | 2022/20 Gaz | CH | Ablehnung |
| 03. Mai 2022 | 2022/20 Gaz | BR | Ablehnung |
| 14. April 2022 | 2022/16 Gaz | JP | Ablehnung |
| 28. März 2022 | 2022/18 Gaz | IL | Ablehnung |
| 23. März 2022 | 2022/14 Gaz | AU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 09. Februar 2022 | 2022/6 Gaz | CO | Ablehnung |
| 01. Februar 2022 | 2022/5 Gaz | NZ | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 18. Januar 2022 | 2022/4 Gaz | NO | Ablehnung |
| 17. November 2021 | 2021/46 Gaz | GB | Ablehnung |
| 15. November 2021 | 2021/46 Gaz | EM | Ablehnung |
| 04. November 2021 | 2021/46 Gaz | IL | Ablehnung |
| 20. Oktober 2021 | 2021/42 Gaz | TR | Ablehnung |
| 08. Oktober 2021 | 2021/41 Gaz | NZ | Ablehnung |
| 27. September 2021 | 2021/39 Gaz | RU | Ablehnung |
| 30. August 2021 | 2021/36 Gaz | CN | Ablehnung |
| 13. Juli 2021 | 2021/29 Gaz | AU | Ablehnung |
| 05. Juli 2021 | 2021/28 Gaz | IN | Ablehnung |
| 29. Dezember 2020 | 2021/23 Gaz | US | Eintragung |
ID: 141597990